GlassScriptPhysician profile
David M Salib
NPI 1053367946
$3,114.17
in general payments reported to CMS, 2019-2025
22 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $46.94 · 2021: $401 · 2022: $348 · 2023: $943 · 2024: $385 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.50 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $579.43 | 2019-2025 | Eylea, Eylea Hd |
| Tearlab Corp | $549.80 | 2019 | |
| Abbvie INC. | $508.25 | 2022-2025 | Ozurdex, Durysta |
| Allergan, INC. | $361.42 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $204.87 | 2020-2025 | Acthar |
| Genentech USA, INC. | $171.90 | 2022-2025 | Vabysmo |
| Dutch Ophthalmic, USA | $171.51 | 2023 | Eva, Combined Machine, Tissueblue |
| New World Medical,INC. | $103.38 | 2023 | |
| Amgen INC. | $59.65 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $54.16 | 2024-2025 | Syfovre |
| Oyster Point Pharma, INC. | $52.85 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $47.07 | 2022-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $44.03 | 2025 | Iluvien |
| Bausch & Lomb Americas INC. | $37.81 | 2023-2025 | Xipere, Miebo |
| Sun Pharmaceutical Industries INC. | $27.36 | 2023 | Cequa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $24.31 | 2025 | Tryptyr |
| Kala Pharmaceuticals, INC. | $24.21 | 2021 | |
| Harrow Eye, LLC | $22.67 | 2025 | Vevye |
| Dompe US, INC. | $19.48 | 2025 | Oxervate |
| Alimera Sciences, INC. | $18.96 | 2023 | Iluvien |
| Johnson & Johnson Surgical Vision, INC. | $18.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Salib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.